On Tuesday, Novartis NVS CEO Vas Narasimhan said the Trump administration's "most favored nation" (MFN) drug pricing policy ...

On May 12, 2025, President Donald Trump signed the executive order (EO) “Delivering Most-Favored-Nation Prescription Drug Pricing To American Patients.” The EO sets forth policy positions that attempt ...

When the Trump administration announced its Most Favored Nation policy, it was portrayed as a simple, sensible idea. Drug ...

Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally ...

The Trump Administration has announced its desire to impose price controls on drugs – officially called a most favored nation (MFN) policy. Essentially, the policy sets the price for the targeted ...

As part of a broader resurgence in pharmaceutical pricing reform and manufacturing policies in 2025, President Donald Trump and bipartisan congressional leaders have introduced contemporaneous ...

The MFN executive order aims to reduce US drug prices by aligning them with international prices, facing legal and industry challenges. Pharmacy benefit managers (PBMs) significantly influence US drug ...

Half of the experts, members of the Cornell Health Policy Insight Panel, indicated MFN pricing would substantially reduce net US drug prices, while half disagreed or were uncertain about the effects.

President Donald Trump has introduced a new website designed to provide patients with access to discounted prices on certain high-cost prescription drugs in the U.S. As the current administration ...

On July 31, the Trump administration called on drug manufacturers to lower prescription drug prices in the U.S. to "most favored nation" – or MFN – pricing, the lowest cost paid for the same ...

President Donald Trump has found himself in an odd juxtaposition as traditional allies are pushing back on his Most Favored Nation (MFN) plan to reduce the price of prescription drugs. In a letter to ...

In an effort to battle against what members feel is an existential threat to their businesses, a group of 10 domestic biotech companies has launched the Midsized Biotech Alliance of America (MBAA) ...